On the 1st of October, Invitrocue brought together international experts to discuss innovations in oncology and the potential of Onco-PDO as a disruptive diagnostic with KOLs. Invitrocue’s CEO Steven Fang and VP of Operations Martin Bach were joined by CEO of Invitrocue Europe Dr. Andreas Lindner, Prof Gopal Lyer from National Cancer Centre Singapore, Prof Arial Zeng from Institute of Biochemistry and Cell Biology, Prof Alastair Steward from University of Melbourne, and Prof Louis Chow Wing Cheong from UNIMED Medical Institute in Hong Kong, at the Klinikum Rechts der Isar der Technischen Universität München in Germany.
